Anti-CD9 [P1/33/2]

Absolute Antibody

Anti-CD9 [P1/33/2]

7

This antibody recognises CD9 which is a glycoprotein with four transmembrane domains that is expressed on the surface of various blood cells, such as B lymphocytes, platelets, monocytes and others, and also on neurons and glia on the periphery. It is impl

Antibodies against CD9 might be used in characterisation of acute leukaemias, other tumours and for functional studies on platelets. For instance, one group used P1/33/2 during immunohistochemical characterisation of frozen sections of melanoma ABCG2+IGR37 cells xenografts (Taghizadeh et al., 2010). Another group used this antibody (along with other anti-CD9 antibodies) to analyse CD9 expression level and distribution in different breast cancer cells (MDA, MA-11, and MCF-7) and they showed that CD9 might be a useful marker of the neoplastic cells as its expression was higher in cancer cells than in normal breast cells as well as it was additionally present in the nuclei of the malignant tissue (Rappa et al., 2014).

Flow Cytometry, ImmunoHistoChemistry

IHC; FC

Research Use Only

Monoclonal

P1/33/2

CD9

CD9 molecule

5H9 antigen; antigen CD9; BA-2/p24 antigen; BTCC-1; CD9 antigen; CD9 antigen (p24); cell growth-inhibiting gene 2 protein; DRAP-27; leukocyte antigen MIC3; MIC3; motility related protein-1; MRP-1; tetraspanin-29; TSPAN29; TSPAN-29

Human

IgG1

CD9 antigen

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

Human

This antibody was raised by immunising mice with acute lymphoblastic leukaemia cells.

-20°C,2°C to 8°C

12352203